AliveCor ECG

The investigation compared tests from 204 STEMI patients presenting in five different settings. 

The not-yet-FDA-cleared device uses three electrodes to create a more detailed reading than existing consumer devices.

Over the weekend AliveCor announced that its technology was validated in two studies.

The results are in for the Scripps Translational Science Institute’s Wired For Health study, and there’s no sugar-coating it: they’re disappointing for those working in digital health.

Utah health system Intermountain Healthcare -- and other, as yet unknown providers -- appear to be investigating AliveCor's smartphone ECG device in a clinical context, to determine whether the iPhone version of the device is comparable with traditional 12-lead ECGs.

AliveCor launched its new third generation smartphone-connected EKG device, a model that is both slimmed down and considerably cheaper than its predecessors.

Japan-based medical device company Omron Healthcare has partnered with AliveCor to help bring AliveCor's FDA-cleared smartphone-connected electrocardiogram (ECG) to more online and brick and mortar retailers.

Smartphone-enabled ECG medical device maker AliveCor and Greatcall, which makes a line of mobile phones and health services marketed to seniors, have partnered to bring the AliveCor device to GreatCall phones.

AliveCor has received an additional FDA 510(k) clearance, this time for an algorithm that allows its smartphone ECG to detect atrial fibrillation -- an abnormal heart rhythm that isn't always detectable to the patient, but if left untreated can lead to stroke or congestive heart failure -- with high accuracy.

The Center for Medicaid and Medicare Services (CMS) has released an unpublished proposed rule that will soon lead to changes in coverage under Medicare Part B.